InMode Ltd. is a medical device company that develops, manufactures, and markets energy-based, minimally invasive surgical and non-invasive aesthetic treatment platforms. The company utilizes proprietary radio frequency (RF) technologies to address face and body contouring, medical aesthetics, and women’s wellness. Its product portfolio includes platforms such as BodyTite, Morpheus8, Contoura, and ApexRF, which are used by plastic surgeons, dermatologists, and OB/GYNs for procedures including liposuction with skin tightening, hair reduction, and treatment of Genitourinary Syndrome of Menopause. InMode also provides post-sales training and support services to physicians. The company was incorporated in 2008 and changed its name from Invasix Ltd. to InMode Ltd. in 2017. It serves customers in the United States, Europe, Asia-Pacific, and Latin America.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage inmodemd.com
Sector Healthcare IR page —
Tags
radio frequency, aesthetic medicine, body contouring, minimally invasive surgery, skin tightening, hair reduction, women's wellness, medical aesthetics, plastic surgery, dermatology, BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, Morpheus8, EmpowerRF, Define, Envision, IgniteRF, OptimasMAX, Luxora, ApexRF, Solaria, Invasix Inc.
Press page —

Metrics

Valuation  
Market cap $ 897.793M
Market cap (USD) $ 897.793M
P/E 9.91
PEG —
P/BV 1.31
P/S 2.42
P/OCF 10.53
P/FCF 10.65
Dividend yield —
Turnover / mcap —
Returns  
ROE 13.5%
ROI 24.3%
ROIC 18.8%
Profit margin 25.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -16.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 370.495M 394.818M 492.048M 454.271M 357.565M 206.107M 156.361M 100.162M
Net profit 93.831M 181.275M 197.919M 161.52M 164.971M 75.03M 61.145M 22.371M
Free cash flow 84.285M 131.995M 176.121M 180.003M 173.946M 78.762M 61.513M 36.505M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 14.69 16.7 22.24 35.7 70.58 47.48 39.2 —
Price performance 12m -0.12 -0.25 -0.38 -0.49 0.49 0.21 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 7.01M 6.63M 10.5M 20.2M 27M 42.4M 36.3M 43.5M
↳ YoY growth -5.4% +58.4% +92.7% +33.4% +56.9% -14.2% +19.7%
↳ 5y CAGR +43.3% +40.5% +32.9%
Lease liabilities (USD) — — — 1.42M 358,000 3.31M 3.51M 6.61M 7.82M 8.23M
Cash and deposits (USD) 6.7M 17.6M 24.7M 44.7M 68.9M 68.1M 97.5M 144M 155M 303M
Right-of-use assets (USD) — — — 1.37M 1.15M 4.32M 5.07M 9.7M 8.73M 8.27M
Cash flow detail
Operating cash flow (USD) — 14.6M 36.9M 62.2M 79.2M 175M 182M 177M 133M 85.3M
Purchases of property, plant and equipment (USD) — -189,000 -381,000 -693,000 -463,000 -939,000 -1.58M -705,000 -669,000 -972,000
Change in receivables (cash effect) (USD) — -2.7M -571,000 449,000 -4.42M -10.5M -10.4M -16.1M 5.95M -7.45M
Change in inventories (cash effect) (USD) — -2.34M -1.89M -2.45M -5.58M -6.04M -18.9M -5.2M -14.5M -14.5M
Change in payables (cash effect) (USD) — 1.51M 541,000 92,000 2.71M 2.37M 7.46M -2.28M -184,000 4.13M
Share buybacks (cash effect) (USD) — — — — -17.2M -35.4M -42.6M 0.00 -285M -127M
Income taxes paid (cash effect) (USD) — -737,000 -1.8M -1.42M -217,000 -1.66M -25.8M -31.6M -17.7M -14.9M
Share-based compensation (USD) — 2.44M 1.95M 1.56M 12.8M 12M 24.5M 23.6M 16.6M 11.1M
Operating cash flow before change in receivables (USD) — 17.3M 37.5M 61.8M 83.6M 185M 192M 193M 127M 92.7M
Free cash flow (OCF - PPE - intangibles) (USD) — 14.4M 36.5M 61.5M 78.8M 174M 180M 176M 132M 84.3M
Income detail
Research and development expense (USD) — 2.58M 4.18M 5.7M 9.47M 9.53M 12.4M 13.4M 13.1M 13.3M
↳ 5y CAGR +37.0% +26.3% +18.2% +7.1%
Total comprehensive income (USD) — 9.19M 22.2M 61.2M 75.3M 163M 155M 204M 183M 94.2M
Comprehensive income to owners (USD) — 9.19M 22.2M 61.2M 75.3M 163M 155M 204M — —
Provision for credit losses (USD) — 186,000 -33,000 78,000 442,000 516,000 449,000 1.02M 572,000 454,000
Credit cost ratio (credit losses / average receivables) (%) — — — 1.1% 5.2% 3.4% 1.9% 2.9% 1.5% 1.1%
Reported Feb 18, 2020 Feb 18, 2020 Feb 18, 2020 Feb 18, 2020 Feb 10, 2021 Feb 10, 2022 Feb 14, 2023 Feb 13, 2024 Feb 4, 2025 Feb 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

YOKNEAM, Israel, November 11, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter of 2026.

Third Quarter 2026 Highlights:

● Quarterly GAAP revenues of $92.1 million, broadly in line with the third quarter of 2025.

● Quarterly revenues from consumables and service of $19.3 million, a decrease of 3% compared to the third quarter of 2025.

● GAAP operating income of $17.5 million and *non-GAAP operating income of $20.5 million.

● Total cash position of $512.7 million as of September 30, 2026, including cash and cash equivalents, marketable securities and short-term bank deposits.

● Successful initial launch of Morpheus8 Max, with continued growth anticipated.

U.S.

October 26, 2026

The Special Committee (the “Committee”) of the Board of Directors (the “Board”) of InMode Ltd. (“InMode” or the “Company”) is writing to provide an update on its continuing work and to reaffirm the principles guiding its review. The Committee remains active and continues to discharge its mandate diligently and independently, with the objective of identifying the course of action that best serves the Company and all of its shareholders.

Continuity of the Committee’s Mandate

Following expiration of the proposal submitted by the group including Meir Shamir and the Company’s Chief Executive Officer, the Board considered it appropriate, in the interest of efficiency and the proper continuation of the process, to keep the Committee in place. Maintaining the Committee preserves continuity and enables its work to proceed within an established framework of independent review.

The Committee’s authority derives from the mandate conferred to it by the Board, not from whether any particular party agrees with its decisions.

Prompts

InMode Ltd. (ticker INMD), listed in United States.

ETFs Holding InMode Ltd.

ETF Weight in ETF Shares Market value As of
JPSV 0.66% 14,414 $ 186.229K Nov 17, 2026
AFSM 0.42% 46,681 $ 613.855K Nov 16, 2026
SCDS 0.28% 1,956 $ 25.272K Nov 17, 2026
SEIS 0.19% 74,762 $ 1.093M Jun 30, 2026
AVDS 0.02% 5,329 $ 70.076K Nov 16, 2026
EBI 0.00% 4 $ 59.84 Aug 31, 2026
AVDE 0.00% 25,114 $ 330.249K Nov 16, 2026
AVDV 0.00% 23,405 $ 307.776K Nov 16, 2026